Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-viral precision T cell receptor replacement for personalized cell therapy
Susan P. Foy, Kyle Jacoby, Daniela A. Bota, et al.
Nature (2022) Vol. 615, Iss. 7953, pp. 687-696
Open Access | Times Cited: 179

Showing 1-25 of 179 citing articles:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 439
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Estelle Baulu, Célia Gardet, Nicolas Chuvin, et al.
Science Advances (2023) Vol. 9, Iss. 7
Open Access | Times Cited: 197
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Cristina Puig-Saus, Barbara Sennino, Songming Peng, et al.
Nature (2023) Vol. 615, Iss. 7953, pp. 697-704
Open Access | Times Cited: 99
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Connor A. Tsuchida, Nadav Brandes, Raymund Bueno, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4567-4582.e20
Open Access | Times Cited: 90
Clinical delivery of circular RNA: Lessons learned from RNA drug development
Tiana L. Young, Kevin Chang Wang, Andrew Varley, et al.
Advanced Drug Delivery Reviews (2023) Vol. 197, pp. 114826-114826
Closed Access | Times Cited: 67
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
Qiaofei Liu, Jiayi Li, Huaijin Zheng, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 66
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Christopher A. Klebanoff, Smita S. Chandran, Brian M. Baker, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 12, pp. 996-1017
Open Access | Times Cited: 62
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Melanie Ayala Ceja, Mobina Khericha, Caitlin Harris, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 2
Open Access | Times Cited: 62
Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
Michael Hiltensperger, Angela M. Krackhardt
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 46
Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities
Mona Meng Wang, Sarah E. Coupland, Tero Aittokallio, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 8, pp. 1212-1224
Open Access | Times Cited: 44
In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy
Wenquan Ou, Samantha Stewart, Alisa White, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 42
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
Sebastian Klobuch, Tom Seijkens, Ton N. Schumacher, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 173-184
Closed Access | Times Cited: 38
Branched chemically modified poly(A) tails enhance the translation capacity of mRNA
Hongyu Chen, Dangliang Liu, Jianting Guo, et al.
Nature Biotechnology (2024)
Closed Access | Times Cited: 28
Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy
Mingming Zhao, Xiaohui Cheng, Pingwen Shao, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
Maria R. Parkhurst, Stephanie L. Goff, Frank J. Lowery, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2586-2595
Open Access | Times Cited: 19
Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review
Aleksandra Golonko, Tomasz Pienkowski, Renata Świsłocka, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 18
Adoptive T cell therapy for solid tumors: current landscape and future challenges
Víctor Albarrán, María San Román, Javier Pozas, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 17
Targeted nonviral delivery of genome editors in vivo
Connor A. Tsuchida, Kevin Wasko, Jennifer Hamilton, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 11
Open Access | Times Cited: 16
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Antonino Glaviano, Hannah Lau, Lukas M. Carter, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 5
Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells
Ce Luo, Rui Zhang, Rui Guo, et al.
Immunity (2025)
Closed Access | Times Cited: 2
The Potential Revolution of Cancer Treatment with CRISPR Technology
Dimitrios Stefanoudakis, Nikhita Kathuria‐Prakash, Alexander W. Sun, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1813-1813
Open Access | Times Cited: 39
A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment
Xianguang Yang, Baohong Zhang
Functional & Integrative Genomics (2023) Vol. 23, Iss. 2
Closed Access | Times Cited: 37
Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond
Sebastian Bittner, Thomas Hehlgans, Markus Feuerer
Trends in Immunology (2023) Vol. 44, Iss. 6, pp. 468-483
Open Access | Times Cited: 36
Computational immunogenomic approaches to predict response to cancer immunotherapies
Venkateswar Addala, Felicity Newell, John V. Pearson, et al.
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 28-46
Open Access | Times Cited: 33
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
Rami Yossef, Sri Krishna, Sivasish Sindiri, et al.
Cancer Cell (2023) Vol. 41, Iss. 12, pp. 2154-2165.e5
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top